|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for ROCK1 |
 Gene summary |
| Basic gene Info. | Gene symbol | ROCK1 |
| Gene name | Rho-associated, coiled-coil containing protein kinase 1 | |
| Synonyms | P160ROCK|ROCK-I | |
| Cytomap | UCSC genome browser: 18q11.1 | |
| Type of gene | protein-coding | |
| RefGenes | NM_005406.2, | |
| Description | Rho kinasep160 ROCK-1p160-ROCKrenal carcinoma antigen NY-REN-35rho-associated protein kinase 1rho-associated, coiled-coil-containing protein kinase 1rho-associated, coiled-coil-containing protein kinase I | |
| Modification date | 20141222 | |
| dbXrefs | MIM : 601702 | |
| HGNC : HGNC | ||
| HPRD : 03414 | ||
| Protein | UniProt: Q13464 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_ROCK1 | |
| BioGPS: 6093 | ||
| Pathway | NCI Pathway Interaction Database: ROCK1 | |
| KEGG: ROCK1 | ||
| REACTOME: ROCK1 | ||
| Pathway Commons: ROCK1 | ||
| Context | iHOP: ROCK1 | |
| ligand binding site mutation search in PubMed: ROCK1 | ||
| UCL Cancer Institute: ROCK1 | ||
| Assigned class in mutLBSgeneDB | B: This gene belongs to targetable_mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID | GO:0007159 | leukocyte cell-cell adhesion | 12082081 | GO:0022614 | membrane to membrane docking | 12082081 | GO:0050900 | leukocyte migration | 12082081 | GO:0050901 | leukocyte tethering or rolling | 12082081 |
| Top |
| Ligand binding site mutations for ROCK1 |
| Lollipop-style diagram of mutations at LBS in amino-acid sequence. We represented ligand binding site mutations only. (You can see big image via clicking.)  : non-synonymous mutation on LBS, Circle size denotes number of samples. |
 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | F120 | S118F | HNSC | 1 | L107 | K109E | HNSC | 1 | M128 | M128I | LUAD | 1 | D216 | D216Y | LUAD | 1 | V137 | Q138H | LUAD | 1 | M128 | A129T | UCEC | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for ROCK1 |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | D216 | D216Y | -1.108127 | M128 | A129T | -0.90803151 | M128 | M128I | -0.84458674 | L107 | K109E | -0.55135778 | V137 | Q138H | -0.45452297 | F120 | S118F | -0.39764474 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for ROCK1 from PDB |
| Top |
| Differential gene expression and gene-gene network for ROCK1 |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for ROCK1 |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| umls:C0086468 | Prenatal Injuries | 1 | Biomarker |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for ROCK1 |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Gene-centered drug-gene interaction network |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Experimental | DB04707 | HYDROXYFASUDIL | Small molecule |  |
| Experimental | DB07876 | (S)-2-METHYL-1-[(4-METHYL-5-ISOQUINOLINE)SULFONYL]-HOMOPIPERAZINE | Small molecule |  |
| Experimental | DB08162 | 5-(1,4-DIAZEPAN-1-SULFONYL)ISOQUINOLINE | Small molecule |  |
| Experimental | DB08756 | (R)-TRANS-4-(1-AMINOETHYL)-N-(4-PYRIDYL) CYCLOHEXANECARBOXAMIDE | Small molecule |  |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of ROCK1 go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | M77 | FASUDIL | 2esm | A | D216 | M77 | FASUDIL | 2esm | B | D216 | Y27 | (R)-TRANS-4-(1-AMINOETHYL)-N-(4-PYRIDYL)CYCLOHEXANECARBOXAMIDE | 2etr | A | D216 | Y27 | (R)-TRANS-4-(1-AMINOETHYL)-N-(4-PYRIDYL)CYCLOHEXANECARBOXAMIDE | 2etr | B | D216 | 07Q | 1-[(1R)-1-(3-METHOXYPHENYL)ETHYL]-3-(4-PYRIDIN-4-YL-1,3-THIAZOL-2-YL)UREA | 3tv7 | A | D216 | 07R | 1-[(3-HYDROXYPHENYL)METHYL]-3-(4-PYRIDIN-4-YL-1,3- THIAZOL-2-YL)UREA | 3twj | C | D216 | 0HD | 1-(1H-INDAZOL-5-YL)-3-(2-PHENYLETHYL)UREA | 3v8s | B | D216 | 0HD | 1-(1H-INDAZOL-5-YL)-3-(2-PHENYLETHYL)UREA | 3v8s | D | D216 | 4KH | 2-FLUORO-N-[4-(PYRIDIN-4-YL)-1,3-THIAZOL-2-YL]BENZAMIDE | 4yvc | A | D216 | 4KH | 2-FLUORO-N-[4-(PYRIDIN-4-YL)-1,3-THIAZOL-2-YL]BENZAMIDE | 4yvc | B | D216 | 4TW | N-[4-(2-FLUOROPYRIDIN-4-YL)THIOPHEN-2-YL]-2-{3- [(METHYLSULFONYL)AMINO]PHENYL}ACETAMIDE | 5bml | B | F120 V137 D216 | 07Q | 1-[(1R)-1-(3-METHOXYPHENYL)ETHYL]-3-(4-PYRIDIN-4-YL-1,3-THIAZOL-2-YL)UREA | 3tv7 | B | L107 D216 | 07Q | 1-[(1R)-1-(3-METHOXYPHENYL)ETHYL]-3-(4-PYRIDIN-4-YL-1,3-THIAZOL-2-YL)UREA | 3tv7 | C | L107 D216 | 07Q | 1-[(1R)-1-(3-METHOXYPHENYL)ETHYL]-3-(4-PYRIDIN-4-YL-1,3-THIAZOL-2-YL)UREA | 3tv7 | D | L107 D216 | 0HD | 1-(1H-INDAZOL-5-YL)-3-(2-PHENYLETHYL)UREA | 3v8s | A | L107 D216 | 0HD | 1-(1H-INDAZOL-5-YL)-3-(2-PHENYLETHYL)UREA | 3v8s | C | L107 D216 | 4KK | 2-(3-METHOXYPHENYL)-N-[4-(PYRIDIN-4-YL)-1,3-THIAZOL-2- YL]ACETAMIDE | 4yve | A | L107 D216 | 4KK | 2-(3-METHOXYPHENYL)-N-[4-(PYRIDIN-4-YL)-1,3-THIAZOL-2- YL]ACETAMIDE | 4yve | B | L107 D216 | 4TW | N-[4-(2-FLUOROPYRIDIN-4-YL)THIOPHEN-2-YL]-2-{3- [(METHYLSULFONYL)AMINO]PHENYL}ACETAMIDE | 5bml | A | L107 F120 D216 | 07R | 1-[(3-HYDROXYPHENYL)METHYL]-3-(4-PYRIDIN-4-YL-1,3- THIAZOL-2-YL)UREA | 3twj | A | M128 V137 D216 | HFS | HYDROXYFASUDIL | 2etk | A | V137 D216 | HFS | HYDROXYFASUDIL | 2etk | B | V137 D216 | ANP | AMP-PNP | 2v55 | A | V137 D216 | ANP | AMP-PNP | 2v55 | C | V137 D216 | 3NC | CIS-4-AMINO-N-(7-CHLORO-1-OXO-1,2-DIHYDROISOQUINOLIN-6-YL)CYCLOHEXANECARBOXAMIDE | 3ncz | A | V137 D216 | 3NC | CIS-4-AMINO-N-(7-CHLORO-1-OXO-1,2-DIHYDROISOQUINOLIN-6-YL)CYCLOHEXANECARBOXAMIDE | 3ncz | B | V137 D216 | 3NC | CIS-4-AMINO-N-(7-CHLORO-1-OXO-1,2-DIHYDROISOQUINOLIN-6-YL)CYCLOHEXANECARBOXAMIDE | 3ncz | C | V137 D216 | 3NC | CIS-4-AMINO-N-(7-CHLORO-1-OXO-1,2-DIHYDROISOQUINOLIN-6-YL)CYCLOHEXANECARBOXAMIDE | 3ncz | D | V137 D216 | 3ND | (3S,4R)-N-(7-CHLORO-1-OXO-1,4-DIHYDROISOQUINOLIN-6-YL)-4-(4-CHLOROPHENYL)PYRROLIDINE-3-CARBOXAMIDE | 3ndm | B | V137 D216 | 3ND | (3S,4R)-N-(7-CHLORO-1-OXO-1,4-DIHYDROISOQUINOLIN-6-YL)-4-(4-CHLOROPHENYL)PYRROLIDINE-3-CARBOXAMIDE | 3ndm | C | V137 D216 | 3ND | (3S,4R)-N-(7-CHLORO-1-OXO-1,4-DIHYDROISOQUINOLIN-6-YL)-4-(4-CHLOROPHENYL)PYRROLIDINE-3-CARBOXAMIDE | 3ndm | D | V137 D216 | 3J7 | N~1~-[2-(1H-INDAZOL-5-YL)PYRIDO[3,4-D]PYRIMIDIN-4-YL]- 2-METHYLPROPANE-1,2-DIAMINE | 4w7p | A | V137 D216 | 3J7 | N~1~-[2-(1H-INDAZOL-5-YL)PYRIDO[3,4-D]PYRIMIDIN-4-YL]- 2-METHYLPROPANE-1,2-DIAMINE | 4w7p | B | V137 D216 | 3J7 | N~1~-[2-(1H-INDAZOL-5-YL)PYRIDO[3,4-D]PYRIMIDIN-4-YL]- 2-METHYLPROPANE-1,2-DIAMINE | 4w7p | C | V137 D216 | 3J7 | N~1~-[2-(1H-INDAZOL-5-YL)PYRIDO[3,4-D]PYRIMIDIN-4-YL]- 2-METHYLPROPANE-1,2-DIAMINE | 4w7p | D | V137 D216 |
| Top |
| Conservation information for LBS of ROCK1 |
| Multiple alignments for Q13464 in multiple species |
| LBS | AA sequence | # species | Species | A103 | TRKVYAMKLLS | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | A215 | GHLKLADFGTC | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | A86 | VIGRGAFGEVQ | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | D160 | YMPGGDLVNLM | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | D202 | RDVKPDNMLLD | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | D216 | HLKLADFGTCM | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | E154 | LYMVMEYMPGG | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | E89 | RGAFGEVQLVR | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | F120 | RSDSAFFWEER | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | F368 | IDTSNFDDLEE | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | F87 | IGRGAFGEVQL | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | G83 | VVKVIGRGAFG | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | G85 | KVIGRGAFGEV | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | G88 | GRGAFGEVQLV | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | I82 | EVVKVIGRGAF | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | K105 | KVYAMKLLSKF | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | K200 | IHRDVKPDNML | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | L106 | VYAMKLLSKFE | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | L107 | YAMKLLSKFEM | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | L205 | KPDNMLLDKSG | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | M128 | EERDIMAFANS | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | M153 | YLYMVMEYMPG | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | M156 | MVMEYMPGGDL | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | N203 | DVKPDNMLLDK | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | R84 | VKVIGRGAFGE | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | V137 | NSPWVVQLFYA | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | V90 | GAFGEVQLVRH | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | Y155 | YMVMEYMPGGD | 3 | Homo sapiens, Mus musculus, Rattus norvegicus |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |